HUE050452T2 - Nukleáris transzport modulátorok és alkalmazásuk - Google Patents

Nukleáris transzport modulátorok és alkalmazásuk

Info

Publication number
HUE050452T2
HUE050452T2 HUE18164757A HUE18164757A HUE050452T2 HU E050452 T2 HUE050452 T2 HU E050452T2 HU E18164757 A HUE18164757 A HU E18164757A HU E18164757 A HUE18164757 A HU E18164757A HU E050452 T2 HUE050452 T2 HU E050452T2
Authority
HU
Hungary
Prior art keywords
nuclear transport
transport modulators
modulators
nuclear
transport
Prior art date
Application number
HUE18164757A
Other languages
English (en)
Hungarian (hu)
Inventor
Vincent Sandanayaka
Sharon Shechter
Sharon Shacham
Dilara Mccauley
Erkan Baloglu
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49448240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE050452(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of HUE050452T2 publication Critical patent/HUE050452T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE18164757A 2012-05-09 2013-05-09 Nukleáris transzport modulátorok és alkalmazásuk HUE050452T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644802P 2012-05-09 2012-05-09
US201361798188P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
HUE050452T2 true HUE050452T2 (hu) 2021-03-29

Family

ID=49448240

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE18164757A HUE050452T2 (hu) 2012-05-09 2013-05-09 Nukleáris transzport modulátorok és alkalmazásuk
HUE13779943A HUE040427T2 (hu) 2012-05-09 2013-05-09 Nukleáris transzportmodulátorok és felhasználásuk

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE13779943A HUE040427T2 (hu) 2012-05-09 2013-05-09 Nukleáris transzportmodulátorok és felhasználásuk

Country Status (32)

Country Link
US (10) US9096543B2 (enExample)
EP (3) EP3404027B1 (enExample)
JP (5) JP6195909B2 (enExample)
KR (5) KR102163377B1 (enExample)
CN (1) CN104428295B (enExample)
AU (5) AU2013259384B2 (enExample)
BR (1) BR112014027860B8 (enExample)
CA (1) CA2872190C (enExample)
CL (1) CL2014003054A1 (enExample)
CO (1) CO7190242A2 (enExample)
CY (2) CY1120832T1 (enExample)
DK (2) DK3404027T3 (enExample)
EA (1) EA036639B1 (enExample)
ES (3) ES3016982T3 (enExample)
GE (2) GEP20237477B (enExample)
HR (2) HRP20181838T1 (enExample)
HU (2) HUE050452T2 (enExample)
IN (1) IN2014DN09434A (enExample)
LT (2) LT2858991T (enExample)
ME (1) ME03795B (enExample)
MX (1) MX364992B (enExample)
NZ (1) NZ702663A (enExample)
PE (1) PE20150128A1 (enExample)
PL (2) PL3404027T3 (enExample)
PT (2) PT2858991T (enExample)
RS (2) RS58058B1 (enExample)
SG (1) SG11201407268SA (enExample)
SI (2) SI2858991T1 (enExample)
SM (2) SMT201800686T1 (enExample)
UA (2) UA124922C2 (enExample)
WO (1) WO2013170068A2 (enExample)
ZA (1) ZA202004892B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109799A1 (en) 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
JP6106605B2 (ja) 2011-01-17 2017-04-05 カリオファーム セラピューティクス，インコーポレイテッド オレフィン含有核輸送調節剤およびその使用
EP2736883B1 (en) 2011-07-29 2019-09-04 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
JP6005740B2 (ja) 2011-07-29 2016-10-12 カリオファーム セラピューティクス，インコーポレイテッド ヒドラジド含有核輸送調節因子およびその使用
AU2013259384B2 (en) * 2012-05-09 2016-06-02 Biogen Ma Inc. Nuclear transport modulators and uses thereof
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
ES2941292T3 (es) 2013-01-15 2023-05-19 Incyte Holdings Corp Tiazolecarboxamidas y compuestos de piridinecarboxamida útiles como inhibidores de PIM quinasa
EP2968278B8 (en) * 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2014205389A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
AR097431A1 (es) 2013-08-23 2016-03-16 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
PL3143627T3 (pl) * 2014-05-13 2019-01-31 Qsa Global Inc. Urządzenie i sposób dla wzmocnionych źródeł promieniowania gamma irydu
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
MX388170B (es) 2014-08-15 2025-03-19 Karyopharm Therapeutics Inc Polimorfos de selinexor
KR101734529B1 (ko) 2015-05-08 2017-05-11 건국대학교 산학협력단 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
US20200216906A1 (en) * 2015-08-25 2020-07-09 President And Fellows Of Harvard College Methods and compositions relating to the diagnosis and treatment of cancer
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US20190055283A1 (en) * 2016-02-29 2019-02-21 Ohio State Innovation Foundation Aza-peptide aldehydes and ketones
EP3429690A4 (en) * 2016-03-16 2019-10-23 Ionis Pharmaceuticals, Inc. METHOD FOR MODULATING KEAP1
WO2017190087A1 (en) 2016-04-30 2017-11-02 Envision Diagnostics, Inc. Medical devices, systems, and methods for performing eye exams and eye tracking
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CA3087912C (en) 2018-01-10 2023-03-14 Xw Laboratories Inc. Prodrugs of ketamine, compositions and uses thereof
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020092965A1 (en) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
MA54383A (fr) 2018-12-06 2021-10-13 Biogen Ma Inc Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique
CN111606890A (zh) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
CN109928939A (zh) * 2019-02-27 2019-06-25 上海卡洛化学有限公司 一种2,2,6,6-四甲基吗啉的制备方法
KR20220004142A (ko) * 2019-05-01 2022-01-11 카리오팜 쎄라퓨틱스, 인코포레이티드 Xp01 억제제 및 xp01 억제제의 제조에 사용하기 위한 중간체의 제조 방법
CN111145135B (zh) * 2019-12-30 2021-08-10 腾讯科技（深圳）有限公司 一种图像去扰处理方法、装置、设备及存储介质
CN117043542A (zh) 2021-04-01 2023-11-10 阿尔卑斯阿尔派株式会社 操作检测装置
MX2023012427A (es) * 2021-04-21 2024-02-09 Natco Pharma Ltd Proceso mejorado para la preparacion de derivados de 7-(morfolinil)-2-(n-piperazinil) metiltieno [2,3-c] piridina.
JP7737544B2 (ja) 2021-08-13 2025-09-10 エックスダブリューファーマ リミテッド ケタミン誘導体の医薬組成物及び経口剤形
WO2023172855A2 (en) * 2022-03-07 2023-09-14 Kaohsiung Medical University Methods for treating hepatitis b virus infection

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
JP2941950B2 (ja) 1994-11-23 1999-08-30 ニューロゲン コーポレイション 或る種の４−アミノメチル−２−置換イミダゾール誘導体および２−アミノメチル−４−置換イミダゾール誘導体；新規な種類のドーパミン リセプタ亜型特異性リガンド
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
CA2229617A1 (en) 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation
CN1088711C (zh) 1996-04-04 2002-08-07 盐野义制药株式会社 头孢烯化合物及含该化合物的医药
CN101817784B (zh) 1996-04-25 2012-02-01 日产化学工业株式会社 乙烯衍生物和含有该衍生物的杀有害生物剂
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
WO1999050264A1 (en) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
CA2423868C (en) 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
JP3608050B2 (ja) 2001-07-24 2005-01-05 トヨタ自動車株式会社 ロールオーバ判別装置
AU2002327627B2 (en) 2001-09-14 2006-09-14 Methylgene Inc. Inhibitors of histone deacetylase
WO2004037248A2 (en) 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
CA2504511A1 (en) 2002-11-01 2004-05-13 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
CA2512886A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
KR20070050475A (ko) 2004-08-11 2007-05-15 교린 세이야꾸 가부시키 가이샤 신규 환상 아미노 안식향산 유도체
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
US20100130737A1 (en) 2005-02-18 2010-05-27 Takeda Pharmaceutical Company Limited Regulating Agent of GPR34 Receptor Function
AR057891A1 (es) 2005-11-15 2007-12-26 Otsuka Pharma Co Ltd Compuestos de oxazol y composicion farmaceutica
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
EA016464B1 (ru) 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
CN101466670B (zh) 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
DK2014652T3 (da) 2006-04-18 2014-10-13 Nippon Chemiphar Co Aktiveringsmiddel til peroxisom-proliferator-aktiveret receptor
KR101130380B1 (ko) 2006-06-13 2012-04-23 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도
CN100503571C (zh) 2006-07-12 2009-06-24 中国药科大学 四氢异喹啉类衍生物、其制备方法及其医药用途
AU2007277519B2 (en) 2006-07-27 2011-12-22 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP2090570B1 (en) 2006-09-05 2011-11-09 Kyowa Hakko Kirin Co., Ltd. Imidazole derivative
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
US7795457B2 (en) 2007-02-26 2010-09-14 Kosan Biosciences Incorporated Carbamate compounds
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
WO2009003921A1 (en) * 2007-07-04 2009-01-08 Neurosearch A/S Novel pyrazole derivatives useful as potassium channel modulators
MX2012000434A (es) 2009-07-09 2012-04-11 Crescendo Therapeutics Llc Metodo de sanacion de herida y modulacion de cicatriz.
WO2011069039A1 (en) * 2009-12-04 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
WO2011109799A1 (en) 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
JP6106605B2 (ja) 2011-01-17 2017-04-05 カリオファーム セラピューティクス，インコーポレイテッド オレフィン含有核輸送調節剤およびその使用
EP2736883B1 (en) 2011-07-29 2019-09-04 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
JP6005740B2 (ja) 2011-07-29 2016-10-12 カリオファーム セラピューティクス，インコーポレイテッド ヒドラジド含有核輸送調節因子およびその使用
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
AU2013259384B2 (en) * 2012-05-09 2016-06-02 Biogen Ma Inc. Nuclear transport modulators and uses thereof
US20160016916A1 (en) 2013-03-15 2016-01-21 Karyopharm Therapeutics Inc. Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014205389A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11567063B2 (en) 2013-11-15 2023-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for assessing cell viability or predicting cell response to a treatment using cell movement
EP3172214B1 (en) 2014-07-26 2020-05-13 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
MX388170B (es) 2014-08-15 2025-03-19 Karyopharm Therapeutics Inc Polimorfos de selinexor
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2017118940A1 (en) 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
WO2018129227A1 (en) 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation

Also Published As

Publication number Publication date
AU2013259384A1 (en) 2014-12-18
UA118085C2 (uk) 2018-11-26
US10335393B2 (en) 2019-07-02
RS60424B1 (sr) 2020-07-31
LT3404027T (lt) 2020-07-10
KR20200118240A (ko) 2020-10-14
AU2019272017A1 (en) 2019-12-19
US9266843B2 (en) 2016-02-23
AU2019272017B2 (en) 2021-05-27
ES2702279T3 (es) 2019-02-28
US10722497B2 (en) 2020-07-28
JP6195909B2 (ja) 2017-09-13
KR102163377B1 (ko) 2020-10-08
PT2858991T (pt) 2018-12-17
KR20200041986A (ko) 2020-04-22
WO2013170068A2 (en) 2013-11-14
UA124922C2 (uk) 2021-12-15
IN2014DN09434A (enExample) 2015-07-17
BR112014027860B8 (pt) 2024-04-30
BR112014027860B1 (pt) 2022-03-08
CL2014003054A1 (es) 2015-05-15
AU2018201012B2 (en) 2019-12-05
KR102223028B1 (ko) 2021-03-03
CA2872190A1 (en) 2013-11-14
SG11201407268SA (en) 2015-01-29
CN104428295A (zh) 2015-03-18
AU2021221398B2 (en) 2023-08-17
JP2021063104A (ja) 2021-04-22
NZ702663A (en) 2017-03-31
US9585874B2 (en) 2017-03-07
SI3404027T1 (sl) 2020-08-31
AU2021221398A1 (en) 2021-09-16
DK3404027T3 (da) 2020-06-02
CY1120832T1 (el) 2019-12-11
GEAP202213653A (en) 2022-09-12
PL3404027T3 (pl) 2020-09-21
US20210251968A1 (en) 2021-08-19
MX364992B (es) 2019-05-17
KR102095429B1 (ko) 2020-03-31
KR20200041984A (ko) 2020-04-22
JP2018172444A (ja) 2018-11-08
ES3016982T3 (en) 2025-05-12
ZA202004892B (en) 2023-03-29
US11318120B2 (en) 2022-05-03
HK1209420A1 (en) 2016-04-01
LT2858991T (lt) 2018-11-26
ES2794866T3 (es) 2020-11-19
US10058535B2 (en) 2018-08-28
CY1123476T1 (el) 2022-03-24
EP2858991A2 (en) 2015-04-15
EP2858991B1 (en) 2018-08-08
AU2016222459A1 (en) 2016-09-22
CN104428295B (zh) 2017-08-08
JP2020037585A (ja) 2020-03-12
RS58058B1 (sr) 2019-02-28
SMT201800686T1 (it) 2019-01-11
MX2014013551A (es) 2015-01-16
SI2858991T1 (sl) 2018-12-31
KR20150018809A (ko) 2015-02-24
SMT202000347T1 (it) 2020-07-08
US9861614B2 (en) 2018-01-09
US20130317031A1 (en) 2013-11-28
DK2858991T3 (en) 2018-11-26
US9096543B2 (en) 2015-08-04
HUE040427T2 (hu) 2019-03-28
US20200038373A1 (en) 2020-02-06
AU2013259384B2 (en) 2016-06-02
EP3663291A1 (en) 2020-06-10
EA036639B1 (ru) 2020-12-02
PT3404027T (pt) 2020-03-30
US20200230110A1 (en) 2020-07-23
WO2013170068A3 (en) 2014-02-20
US10617677B2 (en) 2020-04-14
EP3663291B1 (en) 2024-12-18
US20150111893A1 (en) 2015-04-23
US20160145246A1 (en) 2016-05-26
CO7190242A2 (es) 2015-02-19
BR112014027860A2 (pt) 2017-06-27
ME03795B (me) 2021-04-20
KR20200115688A (ko) 2020-10-07
US20180289675A1 (en) 2018-10-11
EP3404027B1 (en) 2020-03-04
EP3404027A1 (en) 2018-11-21
GEP20237477B (en) 2023-03-27
HRP20200876T1 (hr) 2020-09-04
HRP20181838T1 (hr) 2018-12-28
JP2015516434A (ja) 2015-06-11
EA201492050A1 (ru) 2015-07-30
US20160354347A1 (en) 2016-12-08
JP6818849B2 (ja) 2021-01-20
CA2872190C (en) 2024-06-25
AU2018201012A1 (en) 2018-03-01
PL2858991T3 (pl) 2019-01-31
US10925859B2 (en) 2021-02-23
US20170319551A1 (en) 2017-11-09
JP2018012715A (ja) 2018-01-25
KR102165177B1 (ko) 2020-10-13
PE20150128A1 (es) 2015-02-23
US20190008833A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
ZA202004892B (en) Nuclear transport modulators and uses thereof
IL261612A (en) Nuclear transfer modulators and their uses
SG10201609097PA (en) Nuclear transport modulators and uses thereof
GB2509400B (en) Rigid-stem lead-in-method and system
SG11201406290QA (en) Pallet and pallet system
ZA201401223B (en) Hydrazide containing nuclear transport modulators and uses thereof
IL235826A0 (en) Diazaspirocycloalkane and azaspirocycloalkane
EP2665362A4 (en) NUCLEAR TRANSPORTER MODULATORS CONTAINING OLEFINS AND USES THEREOF
EP2934342A4 (en) DEVICES AND METHODS OF DISCECTOMY
EP2844247A4 (en) ROR MODULATORS AND ITS USES
PL2904124T3 (pl) Urządzenie manipulacyjne
EP2844259A4 (en) MMR MODULATORS AND USES THEREOF
EP2844260A4 (en) ROR MODULATORS AND ITS USES
IL233652A0 (en) Converted phenylimidazopyrazoles and their use
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
EP2874915A4 (en) MODIFYABLE CONTAINERS AND CONNECTING ELEMENTS
PL2884837T3 (pl) Usprawnienia w urządzeniach do obsługi zwierząt
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201214019D0 (en) SP4 and container